Hantavirus cell entry is promoted by its envelope glycoproteins, Gn and Gc, through cell attachment and by fusion between viral and endosomal membranes at low pH. However, the role of Gn and Gc in receptor binding and cell fusion has not yet been defined. In this work, a sequence presenting characteristics similar to those of class II fusion peptides (FPs) of alphavirus E1 and flavivirus E proteins is identified within the hantavirus Gc glycoprotein. A three-dimensional comparative molecular model based on crystallographic data of tick-borne encephalitis virus E protein is proposed for the Andes virus (ANDV) Gc ectodomain, which supports a feasible class II fusion-protein fold. In vitro experimental evidence is provided for the binding activity of the ANDV FP candidate to artificial membranes, as demonstrated by fluorescence anisotropy assays. Taken together, these results support the hypothesis that the Gc glycoprotein of hantaviruses and of other members of the family Bunyaviridae directs the viral fusion activity and that it may be classified as a class II viral fusion protein.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1099/vir.0.81083-0 | DOI Listing |
bioRxiv
November 2024
Paul G. Allen School for Global Health, Washington State University, Pullman, Washington, 99163, USA.
Multiple viruses that are highly pathogenic in humans are known to have evolved in bats. How bats tolerate infection with these viruses, however, is poorly understood. As viruses engage in a wide range of interactions with their hosts, it is essential to study bat viruses in a system that resembles their natural environment like bat-derived cellular models.
View Article and Find Full Text PDFNPJ Vaccines
November 2024
Clinical Trials Center, Walter Reed Army Institute of Research, Silver Spring, MD, 20910, USA.
Hantaan virus (HTNV) and Puumala virus (PUUV) are pathogenic zoonoses found in Asia and Europe, respectively. We conducted a randomized Phase 1 clinical trial of individual HTNV and PUUV DNA vaccines targeting the envelope glycoproteins (GnGc), as well as a combined HTNV/PUUV DNA vaccine delivered at varying doses using the PharmaJet Stratis® needle-free injection system (NCT02776761). Cohort 1 and 2 vaccines consisted of 2 mg/vaccination of HTNV or PUUV plasmid, respectively.
View Article and Find Full Text PDFNPJ Vaccines
October 2024
Department of Immunology, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi'an, China.
mBio
October 2024
Virology Division, USA Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland, USA.
Nat Commun
July 2024
Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!